1 May 2020
The BDI-40 (which does not include the three Big Caps of Cochlear, CSL and Resmed) recovered most of its Covid-19 Pandemic global downturn losses in April, up 26.7% to $13,953 million – above its August 1, 2019 level.
The benchmark ASX-200 was up 8.8% in April – apart from last month, bdits lowest level since Nov 30, 2016.
The collective market capitalization of the the three Big Caps was up 3.5 percent in April to $188,657, almost reaching its January 30, 2020 level and its third highest on record.
Full details tonight.
BDI-40 v ASX200 Year to April 30, 2020
David Langsam
Editor
Biotech Daily
www.biotechdaily.com.au
+613 9372 2990
